Human RCTHumanRandomizedBlindedControlled
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding, Rachel L. Batterham, Salvatore Calanna, Melanie Davies, Luc F. Van Gaal, et al.
Study design
Methods snapshot
- Population
- Adults with overweight or obesity without diabetes
- Sample size
- 1961
- Intervention
- Semaglutide
- Route
- Subcutaneous
- Dose reported
- 2.4 mg
- Frequency
- Once weekly
- Duration
- 68 weeks
- Control / placebo
- Controlled study
Outcomes
Primary
- Percentage change in body weight
- Proportion achieving ≥5% weight reduction
Results
The study reported greater weight reduction with semaglutide plus lifestyle intervention than with placebo plus lifestyle intervention.
Interpretation
Provides large randomized-trial evidence for the studied obesity indication and protocol, not for unapproved compounded or research products.
Adverse events
Not indexed in the current record.
Limitations
- Results apply to the studied population and combined lifestyle intervention
- Trial duration does not establish lifelong outcomes
Connected records
Original source
Sempre consulte o artigo original para métodos completos, análises e contexto editorial.
Open PubMed record ↗